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Background
There has been no report on the clinical features or natural history of autoimmune hemo-
lytic anemia (AIHA) in the Korean adult population. This study retrospectively analyzed 
the clinical characteristics and long-term outcomes of AIHA in the Korean adults.
Methods
Patients newly diagnosed with AIHA between January 1994 and December 2010 at 
Chungnam National University Hospital were enrolled. Patient characteristics at diag-
nosis, response to treatment, and the natural course of the disease were documented.
Results
Thirty-two patients (31 females and 1 male) with a median age of 48 years (range, 17-86) 
were enrolled. Of these, 21.9% were initially diagnosed with secondary AIHA. Thirteen 
patients (40.6%) were initially diagnosed with Evans' syndrome. Of the 29 patients who 
were placed on therapy, 27 (93.1%) showed a partial response or better. Nevertheless, 
1 year after initiating treatment, 80% of the patients were still treatment-dependent. 
During follow-up (median length 14 months; range, 0.5-238), 14 of 25 patients (56.0%) 
who were initially diagnosed with primary warm antibody AIHA were found to have sys-
temic lupus erythematosus (SLE). Median time to conversion to SLE was 8.0 months (95% 
CI, 4.3-11.7), and the probabilities of conversion at 12 and 24 months were 63% and 91%, 
respectively. Younger age (＜60 years) and a positive fluorescent anti-nuclear antibody 
test were associated with a higher probability of SLE conversion (P=0.01 and P＜0.001, 
respectively). 
Conclusion
Primary AIHA is rare. Regular, vigilant testing for SLE is required in patients initially diag-
nosed with AIHA.
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INTRODUCTION
Autoimmune hemolytic anemia (AIHA) is defined as the 
increased destruction of red blood cells (RBCs) in the pres-
ence of anti-RBC autoantibodies [1]. AIHA is a relatively 
uncommon cause of anemia. Recent population-based studies 
have calculated the incidence of AIHA to be 0.8/100,000/year 
[2], and its prevalence to be 17/100,000 [3]. AIHA may be 
primary (idiopathic) or secondary to various diseases, includ-
ing systemic autoimmune disorders [4-6], malignancies [7], 
and infections [8, 9]. AIHA can also be induced by certain 
drugs [10, 11]. This disorder is heterogeneous with respect 
to the type (warm or cold) of antibodies involved. In spite 
of a long history of this disorder, management of AIHA 
is still mainly based on empirical data and on the results 
of small, retrospective, uncontrolled studies. Therapies for 
AIHA have been reviewed by several experts [12-15], but 
treatment guidelines have not yet been established. The cur-
rent recommendations for the diagnosis and management 
of this disorder originate from Western Europe and North 
America, where the epidemiology of hematologic disorders 
may be different from that in the Orient. Although a few 
studies have described the clinical characteristics of AIHA Korean J Hematol 2011;46:111-7.
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in the Asian populations [11, 16-20], information from Asian 
regions is still limited. Furthermore, there has been no report 
on the clinical features or natural history of AIHA in the 
Korean adults. In the present study, we retrospectively ana-
lyzed clinical characteristics and outcomes of patients with 
AIHA in our institute.
MATERIALS AND METHODS
1. Patients
Patients who were consecutively diagnosed with AIHA 
based on positive results to either Coombs' test or cold ag-
glutinin assay, at Chungnam National University Hospital 
between January 1994 and December 2010, were enrolled. 
All patients were Koreans. Patients with drug-induced hemo-
lytic anemia were excluded. All patients underwent the fol-
lowing laboratory investigations: CBC with reticulocyte 
counts, peripheral blood smear, chemistry (including lactate 
dehydrogenase [LDH] and direct and indirect bilirubins), 
urine analysis, serum haptoglobin, plasma hemoglobin, direct 
and indirect Coombs' tests, and cold agglutinin assay. Screen-
ing tests for SLE, including fluorescent anti-nuclear antibody 
(FANA), complement-3 (C3), and -4 (C4) tests, were also 
performed. Patients who were positive for FANA underwent 
additional studies for autoantibodies, such as anti-double 
strand (ds) DNA antibody and anti-Smith antibody. Lupus 
anticoagulants (LA) and anti-cardiolipin antibodies (aCL) 
were examined. Bone marrow studies were performed to 
rule out lymphoproliferative disorders. SLE was diagnosed 
according to the American College of Rheumatology revised 
classification criteria for SLE [21]. Patients fulfilling only 
3 of the revised classification criteria for SLE from the 
American College of Rheumatology were defined as having 
“incomplete” SLE [22]. Evans' syndrome was diagnosed, if 
the patient tested positive for hemolytic anemia by the 
Coomb's test, and for idiopathic thrombocytopenic purpura, 
in the absence of any known underlying etiology.
2. Treatment and response evaluation
Patients with AIHA who did not present with Evans' 
syndrome (hereafter described as “AIHA only”) received oral 
prednisolone (Pd) alone (1 mg/kg/d) or intravenous (IV) 
methylprednisolone (methyl-Pd; 10 mg/kg/d for 3 d) fol-
lowed by Pd, whereas patients with Evans' syndrome re-
ceived corticosteroids (oral Pd alone or IV methyl-Pd fol-
lowed by Pd) or IV immune globulin (IVIg) as first-line 
therapy. Response criteria [22] were classified as follows: 
(a) complete response (CR), defined as a stable hemoglobin 
level of ＞12 g/dL, no requirement for transfusion, and ab-
sence of clinical and laboratory signs of hemolysis (no jaun-
dice, normalization of serum LDH, haptoglobin and indirect 
bilirubin levels, and normal reticulocyte count), irrespective 
of Coombs' test result; (b) partial response (PR), defined 
as a rise in hemoglobin levels of ＞2 g/dL, no or reduced 
transfusion requirement, and improvement of clinical and 
laboratory signs of hemolysis; and (c) no response. 
3. Follow-up 
Patients were followed up every 1-2 weeks until responses 
were achieved, and then every 2-3 months. Investigations 
for SLE were performed annually in most patients. Convert-
sion to SLE and complications such as renal insufficiency 
and thrombosis were evaluated.
4. Statistical analyses
Continuous variables were analyzed using a Student's t- 
test, and binary variables were analyzed using a Chi-square 
test. The probability of conversion to SLE in patients with 
primary AIHA was plotted as Kaplan-Meier curves, and prob-
abilities with respect to risk factors were compared using 
the log-rank test and a Cox proportional hazard model. All 
analyses were performed using SPSS version 17.0 (SPSS Inc., 
Chicago, IL). P-value of ＜0.05 was considered statistically 
significant. 
RESULTS
1. Patient characteristics at diagnosis
Thirty-two patients with a median age of 48 years (range, 
17-86) were enrolled. The majority of the patients (31 of 
32) were female, and 13 (40.6%) presented with Evans' 
syndrome. The occurrence of Evans' syndrome in patients 
initially diagnosed with primary and secondary AIHA was 
36% and 57.1%, respectively. Total bilirubin and LDH levels 
were above the upper normal limit (UNL) in 65.6% and 
90.6% of the patients, respectively. Renal impairment and 
thrombosis were found in 18.8% and 15.6% of the patients, 
respectively. Of the 32 patients, 31 (96.9%) were positive 
for warm antibody, whereas only 1 (3.1%) was positive for 
cold agglutinin. Underlying disorders were found in 7 pa-
tients (21.9%; SLE was found in 5 patients, and lymphoma 
and unidentified lung neoplasm in 1 patient each). No under-
lying disorders were detected in 25 patients (78.1%). There 
were no statistically significant differences between patients 
with AIHA only and those with Evans' syndrome in terms 
of demographic features, CBC, chemistry, complications, au-
toantibody profiles, and etiology, with the exception of lower 
platelet counts in patients with Evans' syndrome (Table 1).
FANA and anti-dsDNA antibody were positive in 16 of 
27 (59.3%) and 12 of 23 (52.2%) patients, respectively. Serum 
levels of C3 and C4 decreased in 14 of 26 (53.8%) and 21 
of 27 (77.8%) patients, respectively. LA and IgG aCL were 
detected in 7 of 17 (41.2%) and 5 of 15 (33.3%) patients, 
respectively. The number of positive results to FANA, anti- 
dsDNA antibody, IgG aCL, IgM aCL, and LA tests, and serum 
levels of C3 and C4, did not differ between patients with 
AIHA only and those with Evans' syndrome (Table 2). As 
anticipated, FANA (100% vs. 52.4%; P=0.03) and anti- 
dsDNA antibody (100% vs. 38.9%; P=0.03) were more fre-
quently positive in patients with SLE than in patients initially 
diagnosed with primary AIHA (data not shown). However, 
there were no statistically significant differences between 
patients initially diagnosed with AIHA and those with AIHA Korean J Hematol 2011;46:111-7.
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Table 2. Serologic findings.
All patients (N=32) AIHA only (N=19) Evans' syndrome (N=13) P
a)
FANA (+) 16/27 (59.3%) 7/14 (50.0%) 9/13 (69.2%) 0.44
FANA titer 1：142±81 1：132±94 1：151±74.2 0.65
Anti-dsDNA antibody (+) 12/23 (52.2%) 6/11 (54.5%)   6/12(50.0%) 1.00
Serum C3 (mg/dL) 51±22.8 52±20.4 49.8±26 0.80
Low serum C3 (＜83 mg/dL) 14/26 (53.8%)   6/13 (46.2%)   8/13 (61.5%) 0.59
Serum C4 (mg/dL) 11.6±10.2 13.9±11.7 9.1±7.9 0.22
Low serum C4 (＜16 mg/dL) 21/27 (77.8%) 10/14 (71.4%) 11/13 (61.5%) 0.43
IgG aCL antibody (+)   5/15 (33.3%)     1/5 (20.0%)   4/10 (40.0%) 0.06
IgM aCL antibody (+)   3/14 (21.4%)  1/5 (20%)     2/9 (22.2%) 1.00
Lupus anticoagulant (+)   7/17 (41.2%)     2/6 (33.3%)    5/11(45.5%)  1.00
a)AIHA only vs. Evans' syndrome.
Abbreviations: AIHA, autoimmune hemolytic anemia; FANA, fluorescent anti-nuclear antibody; aCL, anti-cardiolipin antibody.
Table 1. Patient characteristics.
All patients (N=32) AIHA only (N=19) Evans' syndrome (N=13) P
a)
Age (yrs), median (range) 48 (17-86) 49 (28-84) 47 (17-86) 0.48
Female/male 31/1 18/1 13/0 1.00
Hemoglobin (g/dL)    6.5±2.4    6.3±2.5    6.8±2.3 0.55
MCV (fL)  105±20  107±22  102±19 0.58
Corrected reticulocytes (%)    4.9±3.9    5.4±4.6    4.1±2.7 0.39
RPI    2.3±2.1    2.5±2.5    1.9±1.2 0.41
WBCs (×10
9/L)    8.20±5.43      8.5±5.50    7.70±5.50 0.68
Platelets (×10
9/L)    213±259    337±274    32±25 0.00
AST (IU/L)    59±74    74±92    36±22 0.09
AST＞38 IU/L 19 (59.4%) 13 (68.4%) 6 (46.2%) 0.21
Total bilirubin (mg/dL)    2.8±2.8    3.3±3.4    2.1±1.7 0.23
Total bilirubin ＞1.3 mg/dL 21 (65.6%) 15 (78.9%)   6 (46.2%) 0.07
LDH (IU/L) 1,048±630 1,060±670 1,030±600 0.89
LDH＞400 IU/L 29 (90.6%) 16 (84.2%) 13 (100%) 0.49
Serum haptoglobin (mg/dL)      41±102   54.8±121      8.7±13.3 0.33
Plasma hemoglobin (mg/dL)    26.8±31.7    23.1±32.7    33.9±30.4 0.45
Renal impairment (CCR＜60 mL/min)   6 (18.8%)   2 (10.5%)   4 (30.8%) 0.19
Thrombosis   5 (15.6%) 1 (5.3%)   4 (30.8%) 0.13
Positive Coombs' test 
    Direct 31 (96.9%) 18 (94.7%) 13 (100%) 1.00
    Indirect 29 (90.6%) 17 (89.5%)  12 (92.3%) 1.00
Autoantibody 
    Warm 31 (96.9%) 18 (94.7%) 13 (100%) 1.00
    Cold 1 (3.1%) 1 (5.3%)   0
Etiology at diagnosis
    Primary 25 (78.1%) 16 (84.2%)    9 (69.2%) 0.28
    Secondary   7 (21.9%)   3 (15.8%)    4 (30.8%) 0.96
       SLE   5 (71.4%)   1 (33.3%)   4 (100%)
       Lymphoma   1 (14.3%)   1 (33.3%)   0
       Other   1 (14.3%)   1 (33.3%)   0
a)AIHA only vs. Evans' syndrome.
Abbreviations: AIHA, autoimmune hemolytic anemia; MCV, mean corpuscular volume; PRI, red cell production index; WBC, white blood cell; 
AST, aspartate aminotransferase; LDH, lactate dehydrogenase; CCR, creatinine clearance rate; SLE, systemic lupus erythematosus.
secondary to SLE, in terms of demographic features, CBC, 
chemistry, or complications (data not shown).
2. Response to treatment
Twenty-nine patients were placed on therapy, including 
Pd alone, methyl-Pd followed by Pd, or IVIg followed by 
Pd. More patients with Evans' syndrome received methyl-Pd 
or IVIg than did patients with AIHA only. Of the 29 patients, 
8 (27.6%) and 19 (65.5%) patients achieved complete and 
partial responses within 1 month of treatment initiation, 
respectively. Nevertheless, 2 years after initiating treatment, 
80% of the patients still required Pd or other drugs such 
as azathiopurine or cyclophosphamide to maintain at least 
a partial response. There were no differences in response Korean J Hematol 2011;46:111-7.
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Table 3. Initial treatment and response.
All patients (N=32) AIHA only (N=19) Evans' syndrome (N=13) P
a)
Initial type of treatment 0.02
   Pd only 12/32 (37.5%) 9/19 (47.4%) 3/13 (23.1%)
   Methyl-Pd→Pd 14/32 (43.8%) 7/19 (36.8%) 7/13 (53.8%)
   IVIg→Pd 3/32 (9.4%) 0 3/13 (23.1%)
   Unknown 3/32 (9.4%)  3/19 (15.8%) 0
Response to treatment
b) 0.85
   Complete response   8/29 (27.6%)  4/16 (25.0%)  4/13 (30.8%)
   Partial response 19/29 (65.5%) 11/16 (68.8%)  8/13 (61.5%)
   No response 2/29 (6.9%) 1/16 (6.3%) 1/13 (7.7%)
Pd dependence
c)  
   At 6 months 20/21 (95.2%) 10/11 (90.9%) 10/10 (100%)    1.00
   At 1 yr 16/20 (80.0%)   9/11 (81.8%)      7/9 (77.8%) 1.00
   At 2 yrs 15/19 (78.9%)   9/11 (81.8%)      6/8 (75.0%) 1.00
a)AIHA only vs. Evans' syndrome, 
b)response 1 month after the initiation of treatment, 
c)Pd or other drug dependence.
Abbreviations: Pd, prednisolone; IVIg, intravenous immune globulin.
Table 4. Natural course and complications in patients with warm antibody AIHA.
All patients (N=25) AIHA only (N=16) Evans' syndrome (N=9) P
a)
Follow-up duration (months), median (range)        14 (0.5-238)     24.5 (0.5-180) 13 (2-238) 0.87
Natural course
   Conversion to SLE 12/25 (48.0%)  7/16 (43.8%) 5/9 (55.6%) 0.69
      Time to conversion  (months), median  (range)  9.5 (3-28)   12 (6-22) 6 (3-28) 0.49
   Conversion to incomplete  SLE 2/25 (8.0%) 1/16 (6.3%) 1/9 (11.1%) 1.00
      Time to conversion  (months), median  (range)   7 (6-8) 8 6
   Unchanged   8/25 (32.0%)   5/16 (31.3%) 3/9 (33.3%) 1.00
   Unknown   3/25 (12.0%)   3/16 (18.8%) 0 0.28
Complications
   Renal impairment 2/25 (8.0%) 0 2/9 (22.2%) 0.12
   Thrombosis   3/25 (12.0%) 1/16 (6.3%) 2/9 (22.2%) 0.25
a)AIHA only vs. Evans' syndrome.
Abbreviations: AIHA, autoimmune hemolytic anemia; SLE, systemic lupus erythematosus.
rates or Pd dependence between patients with AIHA only 
and those with Evans' syndrome (Table 3).
3. Natural course of warm antibody AIHA
The natural course and complications were analyzed in 
25 patients who were initially diagnosed with primary warm 
antibody AIHA. During a median follow-up of 14 months 
(range, 0.5-238), 12 patients (48.0%) developed SLE with 
a median time to conversion of 9.5 months (range, 3-28). 
Two of these patients (8.0%) were found to have incomplete 
SLE, with a median time to conversion of 7 months (range, 
6-8). Overall, 56% of the patients who were initially diag-
nosed with primary AIHA were found to have SLE or in-
complete SLE during the follow-up. Of these, 8 were AIHA- 
only patients (out of 16 total; 43.8%), and 6 were Evans' 
syndrome patients (out of 9 total; 66.7%), revealing no stat-
istical difference in SLE conversion frequencies between the 
2 groups. The median time to conversion was shorter, but 
not significantly so, in patients with Evans' syndrome (6 
months; range, 3-28) than in patients with AIHA only (12 
months; range, 6-22). Renal impairment and thrombosis de-
veloped in 2 (8.0%) and 3 (12.0%) patients, respectively 
(Table 4, Fig. 1). Kaplan-Meier analysis revealed that the 
median time to conversion to SLE or incomplete SLE was 
8 months (95% CI, 4.3-11.7), and that the probabilities of 
conversion at 12 and 24 months were 63% and 91%, re-
spectively (Fig. 2). Univariate analysis using the log-rank 
test revealed that age ＜60 years (P=0.01) and a positive 
FANA test (P＜0.001) were risk factors for conversion to 
SLE. Multivariate analysis using a Cox proportional hazard 
model indicated that these 2 parameters were independent 
risk factors (P=0.01 and P=0.001, respectively). Severe ane-
mia (hemoglobin ＜6.0 g/dL), thrombocytopenia, elevated 
serum LDH levels, low serum C3 or C4 levels, and renal 
impairment or thrombosis did not increase the risk of con-
version to SLE (Table 5). Although patients with Evans' 
syndrome tended to develop SLE earlier than did those with 
AIHA only, the difference was not statistically significant 
(Fig. 2). SLE was found much earlier in most patients with 
Evans' syndrome than in those with AIHA only, with the 
exception of a single patient with Evans' syndrome who 
was diagnosed with SLE long after the initial diagnosis. This Korean J Hematol 2011;46:111-7.
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Fig. 1. Natural course of patients 
with warm antibody AIHA.
Fig. 2. Probability of conversion to SLE in patients initially diagnosed with primary warm antibody AIHA (N=25). (A) Probability of conversion to 
SLE in all patients. (B) Comparison of SLE conversion probabilities between patients with AIHA only and those with Evans' syndrome.
patient was not followed up for some time, and thus did 
not undergo regular testing for SLE. No AIHA-related mortal-
ity was found, but 1 patient with lung neoplasm died of 
respiratory failure 3 weeks after initial presentation.
DISCUSSION
The present study demonstrate s  t h a t  A I H A  i s  a n  u n -
common hematologic disorder in the Korean adult pop-
ulation and that cold agglutinin disease is extremely rare, 
which may explain why the epidemiology, clinical features, 
and clinical outcomes of AIHA in the Korean adults have 
not been previously described. Primary (idiopathic) AIHA 
is known to be less common than secondary AIHA in the 
Western populations. However, several reports suggest the 
presence of ethnic differences. For example, secondary AIHA 
accounted for 49% and 51% of Coombs'-positive AIHA in 
the Chinese and French populations, respectively [23, 24]. 
In contrast, secondary AIHA was found in only 34.3% of 
cases in the Indian population [19]. In the present study, 
primary AIHA appeared to be much more frequent at diag-
nosis, which contradicts previous observations from the 
Western countries. However, during follow-up, it was re-
vealed that 56% of patients initially diagnosed with primary 
AIHA actually had secondary AIHA, and that SLE dominated Korean J Hematol 2011;46:111-7.
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Table 5. Risk factors for conversion to SLE in patients initially 




   Age＜60 yrs 0.01
   Severe anemia (Hb＜6.0 g/dL)  0.68
   Thrombocytopenia (＜100×10
9/L) 0.67
   High LDH levels (＞400 IU/L) 0.35
   Positive FANA ＜0.001
   Low serum C3 levels (＜83 mg/dL) 0.27
   Low serum C4 levels (＜16 mg/dL) 0.35
   Positive anti-dsDNA antibody 0.61
   Evans' syndrome 0.42
   Renal impairment 0.21
   Thrombosis 0.53
Multivariate analysis
b)
   Age＜60 yrs 0.01
   Positive FANA 0.001
a)Log-rank test, 
b)Cox proportional hazard model.
as an underlying disorder. Only 32% of the patients initially 
diagnosed with primary AIHA were true primary cases. The 
lower frequency of diagnosis of secondary AIHA in Korea 
than in other countries may be attributed to the exclusion 
of a considerable number of patients with secondary AIHA, 
as most SLE patients are primarily seen and managed by 
rheumatologists or nephrologists. Chronic lymphocytic leu-
kemia (CLL) is known to be a common underlying disorder 
in AIHA [25], but is rare in Korea, which may be another 
reason why secondary AIHA is less frequently diagnosed 
and why SLE was the predominant underlying disorder in 
our cases. 
Evans' syndrome is an autoimmune disorder defined by 
the simultaneous or sequential combination of AIHA and 
immune thrombocytopenia or immune neutropenia [26]. It 
may reveal underlying conditions such as SLE and common 
variable immunodeficiency [27]. Although its frequency is 
unknown, Evans' syndrome is known to be a rare disorder. 
A review reported that only 6 of 399 adult patients with 
AIHA (1.5%) were found to have Evans' syndrome [28]. 
In the present study, Evans' syndrome initially accounted 
for 28.1% of the AIHA cases; however, 66.7% of these pa-
tients were found during follow-up to have secondary AIHA 
with SLE. In the final count, patients with Evans' syndrome 
accounted for 9.4% of AIHA cases; this frequency is still 
higher than that reported in the literature. At present, we 
have no explanation for this discrepancy. A nationwide study 
enrolling a large number of patients may reveal whether 
it can be attributed to ethnic differences or not. There were 
no statistically significant differences between patients with 
AIHA only and those with Evans' syndrome in terms of 
clinical features, with the exception of a higher frequency 
of IgG aCL antibody positivity. Given that more Evans' syn-
drome patients than AIHA-only patients had SLE at diagnosis 
of AIHA, the absence of a statistically significant difference 
in clinical features between the two groups may be attributed 
to the small number of patients. Further studies are war-
ranted.
In the present study, we showed that a population of 
patients who were initially diagnosed with primary AIHA 
turned out to have SLE during follow-up. The probability 
of conversion to SLE within 2 years of follow-up was 91%, 
indicating that the majority of AIHA patients will be diag-
nosed with SLE during the first 2 years of follow-up, and 
that true primary AIHA is rare; this is different from the 
Western, Indian, and Chinese reports [19, 23, 24]. This may 
be explained, at least in part, by the fact that SLE is 2-4 
times more frequent, and more severe, among non-white 
populations. SLE is a chronic autoimmune disease with a 
variety of hematological manifestations. Anemia is found 
in approximately 50% of patients, with the chronic form 
of anemia being the most common [29]. An impaired eryth-
ropoietin response and the presence of antibodies against 
erythropoietin may contribute the pathogenesis of this type 
of anemia. Patients with AIHA usually belong to a distinct 
category, characterized by aCL antibodies, thrombosis, 
thrombocytopenia, and renal disease, often in the context 
of secondary anti-phospholipid antibody syndrome [29]. In 
a previous study of a cohort of 1,251 unrelated females with 
SLE, 76 patients (6.1%) were found to have hemolytic anemia 
[30]. The presence of hemolytic anemia was associated with 
a subset of SLE patients characterized by earlier disease onset, 
more severe disease, and a higher likelihood of renal involve-
ment, seizures, serositis, and other cytopenias. It has been 
shown that ethnicity can influence disease manifestations 
at diagnosis of SLE, even within an Oriental population [31]. 
In one study of the Korean population [32], AIHA was found 
in 3.5% of patients with SLE. 
In the present study, we found that some patients who 
were initially diagnosed with primary AIHA developed renal 
insufficiency or thrombosis during follow-up, indicating that 
such patients need to be carefully monitored. The present 
study showed that patients with AIHA aged ＜60 years and 
those who were positive for FANA were at an increased 
risk of conversion to SLE, indicating that patients with these 
features require regular testing for SLE. There was a tendency 
for the patients with Evans' syndrome to develop SLE earlier 
than those with AIHA alone. The fact that the difference 
was not statistically significant may be attributed to the 
small number of patients. One patient with Evans' syndrome 
who did not undergo regular testing for SLE because of 
poor compliance was diagnosed with SLE very late during 
the follow-up, and this greatly affected the result for that 
group.
In conclusion, true primary AIHA is rare. The majority 
of patients with AIHA are found to have SLE during fol-
low-up. Regular, vigilant testing for SLE is required in pa-
tients who are initially diagnosed with primary AIHA.
REFERENCES
1. Packman CH. Hemolytic anemia due to warm autoantibodies: 
new and traditional approaches to treatment. Clin Adv Hematol Korean J Hematol 2011;46:111-7.
Clinical outcomes of AIHA 117
Oncol 2008;6:739-41.
2. Klein NP, Ray P, Carpenter D, et al. Rates of autoimmune diseases 
in Kaiser Permanente for use in vaccine adverse event safety 
studies. Vaccine 2010;28:1062-8.
3. Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. 
Epidemiology of autoimmune diseases in Denmark. J Autoimmun 
2007;29:1-9.
4. Budman DR, Steinberg AD. Hematologic aspects of systemic lu-
pus erythematosus. Current concepts. Ann Intern Med 1977;86: 
220-9.
5. Rosenthal DS, Sack B. Autoimmune hemolytic anemia in sclero-
derma. JAMA 1971;216:2011-2.
6. Giannadaki E, Potamianos S, Roussomoustakaki M, Kyriakou D, 
Fragkiadakis N, Manousos ON. Autoimmune hemolytic anemia 
and positive Coombs test associated with ulcerative colitis. Am J 
Gastroenterol 1997;92:1872-4.
7. Ellis LD, Westerman MP. Autoimmune hemolytic anemia and 
cancer. JAMA 1965;193:962-4.
8. Saif MW. HIV-associated autoimmune hemolytic anemia: an 
update. AIDS Patient Care STDS 2001;15:217-24.
9. Khan FY, A yassin M. Mycoplasma pneumoniae associated with 
severe autoimmune hemolytic anemia: case report and literature 
review. Braz J Infect Dis 2009;13:77-9.
10. Territo MC, Peters RW, Tanaka KR. Autoimmune hemolytic ane-
mia due to levodopa therapy. JAMA 1973;226:1347-8.
11. Shen Y. Autoimmune hemolytic anemia associated with a for-
mulation of traditional Chinese medicines. Am J Health Syst 
Pharm 2009;66:1701-3.
12. Valent P, Lechner K. Diagnosis and treatment of autoimmune 
haemolytic anaemias in adults: a clinical review. Wien Klin 
Wochenschr 2008;120:136-51.
13. King KE, Ness PM. Treatment of autoimmune hemolytic anemia. 
Semin Hematol 2005;42:131-6.
14. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune he-
molytic anemia: recent progress in understanding the immunobi-
ology and treatment. Transfus Med Rev 2010;24:195-210. 
15. Lechner K, Jäger U. How I treat autoimmune hemolytic anemias 
in adults. Blood 2010;116:1831-8. 
16. Yi Y, Zhang GS, Gong FJ, Yang JJ. Multiple myeloma complicated 
by Evans syndrome. Intern Med J 2009;39:421-2.
17. Hara A, Wada T, Kitajima S, et al. Combined pure red cell aplasia 
and autoimmune hemolytic anemia in systemic lupus eryth-
ematosus with anti-erythropoietin autoantibodies. Am J Hematol 
2008;83:750-2.
18. Lim YA, Kim MK, Hyun BH. Autoimmune hemolytic anemia pre-
dominantly associated with IgA anti-E and anti-c. J Korean Med 
Sci 2002;17:708-11.
19. Naithani R, Agrawal N, Mahapatra M, Pati H, Kumar R, 
Choudhary VP. Autoimmune hemolytic anemia in India: clin-
ico-hematological spectrum of 79 cases. Hematology 2006;11:73- 
6.
20. Karasawa M. Autoimmune hemolytic anemia. Nippon Rinsho 
2008;66:520-3.
21. Hochberg MC. Updating the American College of Rheumatology 
revised criteria for the classification of systemic lupus erythema-
tosus. Arthritis Rheum 1997;40:1725.
22. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans 
syndrome in adults: new insight into the disease based on the anal-
ysis of 68 cases. Blood 2009;114:3167-72.
23. Genty I, Michel M, Hermine O, Schaeffer A, Godeau B, Rochant 
H. Characteristics of autoimmune hemolytic anemia in adults: ret-
rospective analysis of 83 cases. Rev Med Interne 2002;23:901-9.
24. Zhang Y, Chu Y, Shao Z. The clinical implications of IgG subclass 
in 84 patients with autoimmune hemolytic anemia. Zhonghua 
Xue Ye Xue Za Zhi 1999;20:524-6.
25. Zent CS, Ding W, Reinalda MS, et al. Autoimmune cytopenia in 
chronic lymphocytic leukemia/small lymphocytic lymphoma: 
changes in clinical presentation and prognosis. Leuk Lymphoma 
2009;50:1261-8.
26. Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary throm-
bocytopenic purpura and acquired hemolytic anemia: evidence 
for a common etiology. AMA Arch Intern Med 1951;87:48-65.
27. Norton A, Roberts I. Management of Evans syndrome. Br J 
Haematol 2006;132:125-37.
28. Silverstein MN, Heck FJ. Acquired hemolytic anemia and asso-
ciated thrombocytopenic purpura: with special reference to 
Evans' syndrome. Proc Staff Meet Mayo Clin 1962;37:122-8.
29. Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in 
systemic lupus erythematosus: from pathophysiology to clinical 
assessment. Ann Rheum Dis 2006;65:144-8.
30. Jeffries M, Hamadeh F, Aberle T, et al. Haemolytic anaemia in a 
multi-ethnic cohort of lupus patients: a clinical and serological 
perspective. Lupus 2008;17:739-43.
31. Thumboo J, Fong KY, Chng HH, et al. The effects of ethnicity on 
disease patterns in 472 Orientals with systemic lupus erythema-
tosus. J Rheumatol 1998;25:1299-304.
32. Lee SY, Chi HS. Hematologic findings in systemic lupus erythe-
matosus. Korean J Clin Pathol 1998;18:14-9.